Cargando…
Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer
PAM4 is a monoclonal antibody showing high specificity for pancreatic ductal adenocarcinoma (PDAC). Humanized PAM4 labeled with (90)Y in combination with low-dose gemcitabine has shown promising therapeutic activity, and is being evaluated in a phase III clinical trial. Prior efforts have suggested...
Autores principales: | Liu, Donglin, Chang, Chien-Hsing, Gold, David V., Goldenberg, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414189/ https://www.ncbi.nlm.nih.gov/pubmed/25595893 |
Ejemplares similares
-
Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin
por: Gold, David V, et al.
Publicado: (2013) -
Airway Mucus and Asthma: The Role of MUC5AC and MUC5B
por: Bonser, Luke R., et al.
Publicado: (2017) -
Immunohistochemical detection of MUC5AC and MUC5B mucins in ferrets
por: Meyerholz, David K., et al.
Publicado: (2023) -
Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma
por: Manne, Ashish, et al.
Publicado: (2021) -
Development of a Serum Biomarker Assay That Differentiates Tumor-Associated MUC5AC (NPC-1C ANTIGEN) from Normal MUC5AC
por: Luka, Janos, et al.
Publicado: (2011)